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The  development  of  morphine-induced  antinociceptive  tolerance  limits  its therapeutic  efﬁcacy  in pain
management.  Atorvastatin,  or competitive  inhibitor  of 3-hydroxy-methyl-glutaryl  coenzyme  A  (HMG-
CoA)  reductase,  is mainstay  agent  in hypercholesterolemia  treatment.  Beyond  the  cholesterol-lowering
activity,  exploration  of  neuroprotective  properties  of this  statin  indicates  its potential  beneﬁt  in central
nervous  disorders.  The aim  of  the  present  study  was  to assess  the  effects  of atorvastatin  in develop-
ment  and  expression  of morphine-induced  analgesic  tolerance  in  male  mice  and  probable  involvement
of  nitric  oxide.  Chronic  and  acute  treatment  with  atorvastatin  10 and  20 mg/kg,  respectively,  could  alle-
viate morphine  tolerance  in  development  and  expression  phases.  Chronic  co-administration  of  nitric
oxide  synthase  (NOS)  inhibitors  including  L-NAME  (non  selective  NOS  inhibitor;  2 mg/kg),  aminoguani-
dine  (selective  inducible  NOS  inhibitor;  50 mg/kg)  and  7-NI  (selective  neuronal  NOS  inhibitor;  15  mg/kg)
with  atorvastatin  blocked  the  protective  effect  of atorvastatin  in tolerance  reversal.  Moreover,  revers-ice ing  the  atorvastatin  effect  was  also  observed  in  acute  simultaneous  treatment  of L-NAME  (5  mg/kg)  and
aminoguanidine  (100 mg/kg)  with  atorvastatin.  Co-treatment  of  guanylyl  cyclase  inhibitor,  ODQ  (chronic
dose:  10  mg/kg  and  acute  dose:  20 mg/kg)  was  associated  with  prevention  of  atorvastatin  anti-tolerance
properties.  Our results  revealed  that  the  atorvastatin  modulating  role  in morphine  antinociceptive  tol-
erance  is mediated  at least  in  part  via  nitric  oxide  in  animal  pain  models  of hot  plate  and  tail  ﬂick.
©  2016 Elsevier  Inc.  All  rights  reserved.. Introduction
Morphine and related opioids, the most potent analgesic class,
ave been widely utilized for acute and chronic pain management.
he clinical utility of opioids is a huge challenge for management
f chronic pain such as cancer pain and neuropathic pain due to
he rapid development of tolerance and hyperalgesia (Marek et al.,
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ezayat1387@gmail.com (S.-M. Rezayat), Dehpour@sina.tums.ac.ir (A. Dehpour).
1 The ﬁrst two authors are considered as the ﬁrst author.
ttp://dx.doi.org/10.1016/j.brainresbull.2016.07.002
361-9230/© 2016 Elsevier Inc. All rights reserved.1991; Mao  et al., 1995; Mayer et al., 1995; Trujillo and Akil, 1991).
The loss of effectiveness after continued exposure or the require-
ment for dose increasing to maintain the same therapeutic effect is
the deﬁnition of tolerance which occurs in two  independent phases
(induction and expression) (Bhargava, 1994; Johnson and Fleming,
1989; Raghavendra and Kulkarni, 1999).Therefore, restoring the
efﬁcacy of these major analgesics is of great importance in clinical
setting.
Statins identiﬁed in 1976 by Endo and colleagues (Endo
et al., 1976). These medications are competitive inhibitors of 3-
hydroxy-methyl-glutaryl coenzyme A (HMG-CoA) reductase which
catalyzes the conversion of HMG-CoA to mevalonate (an early, rate-
limiting step in cholesterol biosynthesis) (Schachter, 2005). Statins
are the best-tolerated and most effective agents for treating dys-
lipidemia (Zhou and Liao, 2009). Statins exert pleiotropic effects
which could be protective in many conditions including neuro-
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ogical disorders, inﬂammation, pain and cardiovascular diseases
Bifulco et al., 2008; Ludman et al., 2009; Reiss and Wirkowski,
009; Rosenson, 2001; Shi et al., 2011; Weitz-Schmidt, 2002; Zhou
nd Liao, 2010). Recently, several landmark experimental trials
emonstrated the beneﬁcial effects of statin therapy for morphine-
nduced analgesic tolerance and dependence. Mansouri et al. (2015)
eported that simvastatin modulates morphine antinociceptive tol-
rance and physical dependence. There is evidence indicating that
osuvastatin attenuates the morphine analgesic tolerance (Li et al.,
015a,b).
Nitric oxide (NO), a potent guanylyl cyclase stimulator, is syn-
hesized by nitric oxide synthase (NOS) from amino acid L-arginine
ia a NADPH-dependent pathway. The recognized isoforms of NOS
re: inducible (iNOS), neuronal (nNOS) and endothelial (eNOS),
he last two enzymes are constitutively expressed (Förstermann
nd Sessa, 2012; Shafaroodi et al., 2012, 2015). Based upon the
revious reports NO and cGMP (cyclic guanosine monophosphate)
ystems mediate opioid antinociception and tolerace/dependence
henomena (Babey et al., 1994; Elliott et al., 1994; Vaupel et al.,
995).
Nitric oxide may  play dual role in both phases of morphine
olerance. Studies suggest that NOS inhibition prevents naloxone-
recipitated withdrawal signs and development and expression
f analgesic tolerance while some reports indicate that inhibi-
ion of NOS accelerates the development of tolerance. (Dambisya
nd Lee, 1996; Kolesnikov et al., 1993). It is well-determined that
lockade of NO overproduction through selective iNOS inhibitors
ttenuates the development of morphine tolerance and depen-
ence and administration of NO donors leads to exacerbation of
pioid withdrawal signs in dependent animals (Abdel-Zaher et al.,
006; Dambisya and Lee, 1996). Data about role of NO in tolerance
nd dependence phenomena are controversial.
It has been presumed that atorvastatin neuroprotection is not
ntirely due to cholesterol reduction but several mechanisms such
s NO/cGMP pathway are responsible in part for the salutary
ffects. Statins rapidly enhance the NO bioavailability which aug-
ents cerebral perfusion, and up-regulates the eNOS expression
ia inhibition of isoprenylation of RhoA GTPase. Statins prolong the
alf-life of NOS, increase the expression of iNOS and nNOS, activate
he eNOS via PI3K/protein kinase Akt pathway and lead to tran-
criptional alteration (Moezi et al., 2012; Stepien´ et al., 2005; van
er Most et al., 2009; Wang et al., 2010).
The current investigation aimed to assess the role of atorvastatin
n development and expression phases of morphine-induced anal-
esic tolerance by two pain models: hot plate and tail ﬂick. We  also
xamined the possible contribution of NO in atorvastatin effects on
orphine analgesic threshold.
. Materials and methods
.1. Subjects
This study was performed on male NMRI (Naval Medical
esearch Institute) mice weighing 23–30 g (Tehran University of
edical Sciences, Iran). Animals were housed in the standard cages
nd maintained under controlled laboratory conditions (tempera-
ure: 24 ± 1 ◦C, humidity: 55 ± 10%, lighting: 12-h light/dark cycle)
ith free access to both standard laboratory pellet chow and tap
ater. All procedures were conducted in compliance with institu-
ional Guideline for the Care and Use of Laboratory Animals with the
pproval of Tehran University Research and Medical Ethics Com-
ittees. All behavioral experiments carried out at the same time
f the day. Each mouse was used only once in this study and each
roup consisted of 6-8 animals. Bulletin 125 (2016) 173–180
2.2. Chemicals
The following drugs were used throughout this study: atorvas-
tatin, a HMG-CoA inhibitor (Sobhan, Iran); morphine, an opioid
agonist (Temad, Iran); L-NAME [L-NG-Nitro-l-arginine methyl
ester hydrochloride], a non-speciﬁc inhibitor of NOS (Sigma,
USA); aminoguanidine, a selective inhibitor of iNOS (Sigma, USA);
7-NI (7-nitro indazole), a selective inhibitor of nNOS (Sigma,
USA); L-arginine, a NO donor (Sigma, USA) and ODQ [1H-[1,2,4]
Oxadiazolo[4,3-a]quinoxalin-1-one], a selective and potent sGC
(soluble guanylyl cyclase) inhibitor (Sigma, USA). Atorvastatin sus-
pension was prepared in carboxymethyl cellulose (CMC, 0.5%) and
was administered trice daily by oral gavage. Morphine, L-NAME,
aminoguanidine, 7-NI and ODQ were given intraperitoneally (i.p.)
in a volume of 10 ml/kg of the mice body weight based on two
protocols which are deﬁned in the treatment section. Morphine,
L-NAME and aminoguanidine were dissolved in sterile isotonic
saline solution. 7-NI and ODQ were prepared as ﬁne suspensions
in sterile isotonic saline using polysorbate 80 and DMSO 1% (w/v)
as co-solvents.
2.3. Induction and assessment of morphine tolerance
Morphine analgesic tolerance was  induced via repeated injec-
tion of morphine trice a day for 5 consecutive days: 50 mg/kg (8:00
a.m), 50 mg/kg (11:00 a.m) and 75 mg/kg (4:00 p.m, higher dose
prevents the withdrawal signs over-night). On  the 5th day ani-
mals received only a single dose of morphine 50 mg/kg (Dambisya
et al., 1991; Homayoun et al., 2002; Javadi et al., 2013). Loss of
antinociceptive property of morphine in hot plate and tail ﬂick tests
was used to assess the degree of tolerance. Hot plate test: animals
were placed separately on an electrically-heated surface (55 ± 1 ◦C)
(Tahghigh-Gostaran-Teb, Iran). To conﬁne the mouse on the heated
surface, an open plexiglas tube (18 cm high × 22 cm diameter) was
used. The time interval (sec) between placement of animal and lick-
ing the hind paws or jumping with all four feet was recorded by a
stopwatch as the end point. The increase in hot plate threshold
was considered as a measure of analgesic activity. In order to avoid
tissue damage animals were removed from the hot plate surface
if they could not respond within 90 s. Animals showing a reaction
time greater than 90 s were excluded from the subsequent experi-
ment. In a trial, prior to drug administration animals were tested for
5 days in order to obtain a standard control reaction time level. The
analgesic effect of morphine was  determined 60 min  after the ﬁrst
morphine injection on the ﬁrst, third and ﬁfth days. Tail ﬂick assay:
the apparatus (Ugo Basile, Italy) was  used to measure response
latencies. Animals were restrained with their tail positioned in tail
ﬂick apparatus. The light beam was  focused on the dorsal surface
of animal’s tail. The time interval between initiation of radiant heat
stimulation and abrupt removal of tail from this noxious stimulus
was considered as tail ﬂick threshold (cut-off time = 10 s) (D’amour
and Smith, 1941). We  applied the tail ﬂick model 45 min after the
ﬁrst treatment on the ﬁrst, third and ﬁfth days. The two tests were
performed on the same group of animals.
2.4. Treatments
To assess the role of atorvastatin in the induction and expression
phases of morphine analgesic tolerance, we designed two proto-
cols. In the protocol one: different doses of atorvastatin (0.01, 0.1,
5, 10, 20 mg/kg) were administered perorally (p.o) trice a day for
5 days 45 min  prior to injection of every dose of morphine and hot
plate/tail ﬂick tests were performed on ﬁrst, third and ﬁfth days.
In the second protocol: different doses of atorvastatin (0.01, 0.1,1,
5, 10, 20 mg/kg) were administered by gavage as single doses only
on the 5th day 45 min  before the last dose of morphine (50 mg/kg)
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Fig. 1. The effect of chronic treatment with different doses of atorvastatin (ATOR) on morphine (MOR)-induced tolerance. ATOR was administered 5 days by gavage 45 min
before  MOR  injection. Data are expressed as mean ± S.E.M of analgesic threshold of 6–8 mice. A: analgesic threshold assessment in hot plate test *P < 0.05, **P < 0.01 and
***P  < 0.001 compared to morphine-treated group. B: analgesic threshold in tail ﬂick test *P < 0.05 compared to MOR-treated group, according to one-way analysis of variance,
followed by Tukey’s post hoc test. C: Induction of morphine analgesic tolerance due to repeated injection of MOR  during 5 days (hot plate). D: Induction of morphine analgesic
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n  the day 1 according to two-way ANOVA repeated measure.
nd analgesic tests were performed 1 h after morphine injection. In
nother experiment we administered these doses of atorvastatin
acute and chronic) alone 45 min  before analgesic tests. To inves-
igate the role of NO in the tolerance modulation by atorvastatin,
OS inhibitors and ODQ were administered to animals based on
ur two protocols. In protocol one: the NOS inhibitors including; L-
AME (2 mg/kg), aminoguanidine (50 mg/kg), 7-NI (15 mg/kg) and
DQ (10 mg/kg) were injected 30 min  after each dose of morphine
75 min  after atorvastatin) during the induction phase. Moreover;
o determine the role of NO in the expression phase of tolerance
-NAME (5 mg/kg), aminoguanidine (100 mg/kg), 7-NI (40 mg/kg)
nd ODQ (20 mg/kg) and L-arginine 60 mg/kg (NO precursor) were
dministered only on 5th day 30 min  after morphine injection
75 min  after atorvastatin). Sub-effective doses of NOS inhibitors,
DQ and L-arginine were selected based on our previous studies
Hassanipour et al., 2016; Javadi et al., 2013).
.5. Statistics
Data are presented as mean ± standard error of the mean
S.E.M). The one-way analysis of variance (ANOVA) followed by
ukey multiple comparisons and two-way ANOVA repeated mea-
ure, followed by Bonferroni post hoc test were used to indicate
he statistical signiﬁcance of differences between the experimen-
al means. P value < 0.05 was considered signiﬁcant for all analyses. to control (CMC)-treated animals, ###P < 0.001 compared to MOR-treated animals
Graph-pad prism software version 6 was used to analyze the data
of analgesic latency.
3. Results
3.1. Effect of chronic atorvastatin administration on the
development of morphine analgesic tolerance
Fig. 1A illustrates the effects of chronic p.o administration of
atorvastatin (0.01, 0.1, 1, 5, 10 and 20 mg/kg) on the analgesic
threshold 45 min  prior to morphine during 5 days. Atorvastatin
(10 mg/kg) signiﬁcantly (P < 0.05) increased the analgesic latency
on day 3 with comparison to morphine-treated animals in day 3, (F
(2, 10) = 30.90, P < 0.001), and also enhanced the threshold on day
5 compared to morphine analgesic effect on day 5, P < 0.001, (F (7,
29) = 46.99, P < 0.001). An atorvastatin dose of 0.1 mg/kg was associ-
ated with the analgesic threshold reduction compared to morphine
analgesic latency and this effect was signiﬁcant as a tolerance wors-
ening effect, (F (7, 28) = 16.55, P < 0.001) for the third day and (F
(7, 29) = 46.99, P < 0.001) for the ﬁfth day. Fig. 1B illustrates that
atorvastatin 20 mg/kg exerts a tolerance-reversal role (P < 0.05) in
tail ﬂick test, (F (7, 40) = 11.40, P < 0.001) and (F (7, 41) = 5.267,
P < 0.001). In addition, other doses of atorvastatin exerted different
patterns on the analgesic latencies in both models. The effective
dose in hot plate and tail ﬂick tests are different which reﬂects dif-
ferent neurologic mechanisms determined by each test. The tail
ﬂick test evaluates reﬂexive and spinally mediated response but
176 M. Hassanipour et al. / Brain Research Bulletin 125 (2016) 173–180
Fig. 2. The effects of different doses of chronic atorvastatin (ATOR) on pain latency following 5 days of atorvastatin administration. Various doses of ATOR were administered
90  min  prior to analgesic tests, 2A for hot plate and 2 B for tail ﬂick methods. Each point represents the mean ± S.E.M for 6–8 mice. *P < 0.05 and ***P < 0.001 to morphine
(MOR)-treated animals. ##P < 0.01 and ###P < 0.001 compared to MOR + ATOR 20 and ATOR 10 + MOR-treated animals.
Fig. 3. The effect of acute treatment with different doses of atorvastatin (ATOR) on morphine (MOR)-induced tolerance. ATOR was administered 45 min  before the last of
MOR  on day 5. Data are expressed as mean ± S.E.M of analgesic threshold of 6–8 mice. A: analgesic threshold assessment in hot plate test, ***P < 0.001 compared to morphine-
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ot plate method measures complex behaviors requiring neuro-
ogical processing in the brain which leads to lifting/licking of a
aw in response to the noxious stimulation (Mulder and Pritchett,
004). The dose of 10 mg/kg was chosen for experiments allowing
etter detection of mechanisms of the observed effects. Fig. 1C and
 show that during 5 days of morphine injection 3 times daily, tol-
rance is induced and the signiﬁcant analgesic effect diminishes or
isappears. Fig. C: in hot plate test (F (5, 26) = 81.91, P < 0.001) and
ig. D: in tail ﬂick test (F (5, 30) = 58.37, P < 0.001).
.2. Effect of different doses of chronic atorvastatin treatment on
he analgesic threshold
We  examined the effects of chronic atorvastatin treatment on
nalgesic threshold in order to exclude the effect of atorvastatin on
nalgesic latency. In several studies an analgesic effect for statins
as reported (Garcia et al., 2011). So, we administered atorvastatin
or 5 days 3 times daily to animals and then performed the hot plate
nd tail ﬂick tests on the ﬁrst, third and ﬁfth days 45 min  after ator-
astatin treatment. Fig. 2A and B show that atorvastatin with the
ose of 10 and 20 mg/kg could not induce an analgesic role per se
n hot plate and tail ﬂick respectively and the analgesic threshold
s signiﬁcantly lower than atorvastatin administration plus mor-
hine on test days (P < 0.001). By these two experiments we can
laim that morphine analgesic tolerance-reversal by atorvastatin is
ot related to analgesic effect of statin at the previously mentioned
oses (F (11, 57) = 54.04, P < 0.001) and (F (5, 27) = 7.301, P < 0.001).d group, according to one-way analysis of variance, followed by Tukey’s post hoc
3.3. Effect of different doses of acute atorvastatin treatment on
the expression of morphine analgesic tolerance
To clarify the role of acute atorvastatin in the expression of
morphine tolerance, we  administered different doses of this drug
(0.01, 0.1, 1, 5, 10 and 20 mg/kg) only once 45 min  before the dose
of morphine on the last day. One-way ANOVA revealed a signiﬁ-
cant effect for atorvastatin (F(6, 32) = 31.38, P < 0.001) in hot plate
test (Fig. 3A). Post-hoc analysis with Tukey’s test revealed a signif-
icant tolerance blocking effect for acute atorvastatin at the dose of
20 mg/kg (P < 0.001) and a tolerance potentiating role for the dose
of 5 mg/kg (P < 0.001). Fig. 3B shows that atorvastatin at the dose of
1 mg/kg could reverse the morphine induced tolerance (P < 0.01),
(F(6, 33) = 7.650, P < 0.001) in tail ﬂick method.
3.4. Acute atorvastatin treatment did not affect the analgesic
threshold
The effect of acute atorvastatin administration on analgesic
threshold is pictured in Fig. 4A/B. Atorvastatin at the dose of 1
and 20 mg/kg did not alter the analgesic threshold in compar-
ison with control group. We administered these doses of drug
45 min  before analgesic tests. These doses were selected based
on the dose response which is clearly deﬁned in Fig. 3. One-way
ANOVA revealed a signiﬁcant effect for morphine in elevating the
threshold (F(2, 17) = 161.2, P < 0.001) (hot-plate, Fig. 4A) and (F(2,
19) = 117.2, P < 0.001) (tail-ﬂick, Fig. 4B). Post hoc analysis with
Tukey test showed that atorvastatin effect on the analgesic latency
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Fig. 4. The effect of different doses of acute atorvastatin (ATOR) administron on pain threshold. ATOR at the single doses of 20 and 1 mg/kg was administered 90 min  prior to
analgesic tests, 4A for hot plate and 4 B for tail ﬂick method. Each point represents the mean ± S.E.M for 6–8 mice. ***P < 0.001 compared to vehicle (CMC)-treated animals,
###P  < 0.001 compared to MOR-treated animals.
Fig. 5. The effects of chronic NOS inhibitors and ODQ administration on morphine (MOR)-tolerance reversal by atorvastatin (ATOR, 10 mg/kg) following 5 days of MOR
t g and ODQ 10 mg/kg were injected 3 times daily 75 min after each dose of ATOR admin-
i  0.001compared to MOR-treated animals, #P < 0.05 and ###P < 0.001compared to ATOR
1 ed by Tukey’s post hoc test.
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Fig. 6. The effects of acute NOS inhibitors and ODQ administration on mor-
phine (MOR)-tolerane reversal by atorvastatin (ATOR, 20 mg/kg) following 5 days
of  MOR  tolerance induction. L-NAME 5 mg/kg, aminoguanidine (AG) 100 mg/kg,
7-NI 40 mg/kg and ODQ 20 mg/kg were injected on the day 5, 30 min after theolerance induction. L-NAME 2 mg/kg, aminoguanidine (AG) 50 mg/kg, 7-NI 15 mg/k
stration. Each point represents the mean ± SEM for 6–8 mice. * P < 0.05 and ***P <
0  mg/kg + MOR-treated animals, according to one-way analysis of variance, follow
t the above mentioned doses is signiﬁcantly lower than morphine
P < 0.001) and the observed thresholds are in the range of control.
.5. Attenuation of tolerance reversal with chronic atorvastatin
dministration by NOS inhibitors and ODQ in hot plate test
To investigate the role of NO in tolerance blocking effect of
torvastatin, L-NAME, a nonspeciﬁc NOS inhibitor, 7-NI, a speciﬁc
NOS inhibitor, ODQ, a speciﬁc sGC inhibitor and aminoguanidine,
 speciﬁc iNOS inhibitor were injected 75 min  after atorvastatin
0 mg/kg 3 times daily for a 5-day time span. As illustrated in
ig. 5, chronic administration of L-NAME 2 mg/kg and aminoguani-
ine 50 mg/kg completely reversed the tolerance blocking effect of
torvastatin in the third and ﬁfth days. 7-NI 15 mg/kg and ODQ
0 mg/kg signiﬁcantly blocked the protective property of ator-
astatin only in the last day. Moreover, L-NAME 2 mg/kg, 7-NI
5 mg/kg, amioguanidine 50 mg/kg and ODQ 10 mg/kg per se did
ot alter the analgesic threshold (data not shown) and these doses
re obtained based on our previous studies (Homayoun et al., 2002;
avadi et al., 2013).
.6. NOS inhibitors and ODQ abrogated the tolerance blocking
ffect of acute atorvastatin at the dose of 20 mg/kg in hot plate test
Fig. 6 illustrates the effects of acute NOS inhibitors and ODQ
o-administration with the protective dose of atorvastatin against
injection of the last dose of MOR. Each point represents the mean ± SEM for 6–8
mice.  ***P < 0.001compared to MOR-treated animals, ###P < 0.001 compared to
ATOR 20 mg/kg + MOR-treated animals, according to one-way analysis of variance,
followed by Tukey’s post hoc test.
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Fig. 7. The effect of L-arginine (L-ARG) on analgesic threshold elicited by hot plate
test in animals treated with acute atorvastatin (ATOR) 10 mg/kg (single dose on day
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o) and chronic morphine (MOR). L-ARG was injected 30 min  after last dose of MOR.
ata were expressed as mean ± S.E.M. N = 8; **P < 0.05 compared to MOR + ATOR
0-treated animals according to one-way ANOVA, followed by Tukey’s post hoc test.
orphine-induced tolerance. Simultaneous administration of L-
AME 5 mg/kg, aminoguanidine 100 mg/kg and ODQ 20 mg/kg
igniﬁcantly (P < 0.001) blocks the tolerance reversing effect of
torvastatin 20 mg/kg based on One-way ANOVA (F(5, 18) = 21.60,
 < 0.001). Post hoc analysis revealed that acute 7-NI administra-
ion did not inhibit the increased latency of analgesia induced by
torvastatin at dose of 20 mg/kg (P > 0.05).
.7. Co-administration of acute L-arginine and atorvastatin
0 mg/kg enhanced the hot plate analgesic threshold in the
xpression phase
The effect of L-arginine, as a NO precursor, was  investigated on
he analgesic latency in the expression phase of morphine-induced
olerance. As shown in Fig. 7, simultaneous administration of L-
rginine 60 mg/kg and subeffective dose of atorvastatin (10 mg/kg)
ed to signiﬁcant (F(2, 10) = 17.36, P < 0.001) potentiation of the
nalgesic threshold (P < 0.01). L-arginine 60 mg/kg is considered as
he subeffective dose based on our previous studies (Hassanipour
t al., 2016).
. Discussion
In the current study, we ﬁrstly observed that acute and chronic
dministration of atorvastatin by oral gavage totally blocked the
xisting morphine analgesic tolerance. Our further investigations
roposed that NO system mediates the tolerance blocking effects
f atorvastatin. Acute and chronic injection of L-NAME prevented
he protective effect of atorvastatin in tolerance reversal. Besides
hat, acute and chronic aminoguanidine administration inhibited
he analgesic threshold enhancement by atorvastatin. Moreover, in
he development phase chronic 7-NI administration prevented the
ffects of atorvastatin, but its acute injection could not alter ator-
astatin activity in the expression phase. Furthermore, acute and
hronic administration of ODQ, a guanylyl cyclase inhibitor, pre-
ented the protective effect of atorvastatin. In the animals received
ub-effective dose of atorvastatin, acute treatment with L-arginine, NO donor, augmented the morphine analgesic activity.
Opioids are still the last resort for moderate to severe pain
ut rapid development of analgesic tolerance (a profound loss
f drug potency) remains as a frustrating problem (Ren et al., Bulletin 125 (2016) 173–180
2015). There are many hypotheses about how opioid tolerance
develops, including, functional decoupling of opioid receptors from
G-proteins which leads to receptor desensitization, phosphoryla-
tion of opioid receptors, internalization and/or down-regulation
of -opioid receptor, upregulation of the cAMP (cyclic adenosine
monophosphate) and PKC (protein kinase C) pathways, neuroim-
mune activation and neuroinﬂammation, glutamate homeostasis,
nitric oxide production, modulatory role of ion channels or neu-
rotrophic factors and activation of glial cells (astrocytes and
microglia) at the level of the spinal cord (Ben-Eliyahu et al., 1992;
Bian et al., 2012; Dang and Christie, 2010; DeLeo et al., 2004;
Fukagawa et al., 2013; Koch and Höllt, 2008; Kolesnikov et al., 1993;
Martini and Whistler, 2007; Ossipov et al., 2004; Vacca et al., 2013).
HMG-CoA reductase inhibitors (statins), known as common
lipid-lowering drugs, have recently been shown to exert mod-
ulatory properties in pain management and morphine analgesic
tolerance (Garcia et al., 2011; Li et al., 2015a,b). Li et al., 2015a,b
showed that rosuvastatin delayed or partially reversed the mor-
phine antinociceptive tolerance in rats. Considering the fact
that chronic morphine treatment activates extracellular signal-
regulated protein kinase (ERK) in both central and peripheral
nervous systems leading to astrocyte activity as well as secretion of
interleukin-1 beta (IL-1) and tumor necrosis factor alpha (TNF)
and eventually central inﬂammation, they suggested that inhibition
of ERK activation is one of the essential mechanisms.
Additionally, rosuvastatin has been found to restore analgesic
effects of morphine after tolerance establishment during neuro-
pathic pain treating in rats (Li et al., 2015a,b). Another studies
indicated that simvastatin modulates analgesic tolerance and phys-
ical dependence in mice (Ghasemi et al., 2015; Mansouri et al.,
2015). The data obtained in different studies demonstrates the
beneﬁcial effects of atorvastatin in decreasing the nociception and
inﬂammation in animal pain models including writhing test, tail
ﬂick test and orofacial formalin test. Analgesic effects of atorvas-
tatin have been mediated through several mechanisms including
up-regulation the expression and activity of NOS, inhibition of
cyclooxygenase-2 production, blocking the release of cytokine and
prostaglandin, immunomodulatory role and possible direct anal-
gesic action on nociceptors (Garcia et al., 2011; Kwak et al., 2000;
Mosheimer et al., 2005; Santodomingo-Garzón et al., 2006).
In the present investigation, consistent with previous reports
about the statin therapy beneﬁts, atorvastatin administration (p.o,
acute and chronic) could restore the antinociceptive effects of mor-
phine following tolerance induction. The effect of atorvastatin on
morphine analgesic tolerance is not dose dependent. Every dose
has exerted a speciﬁc pattern and here is not a deﬁnite trend. Con-
trary to other reports, we did not observe any analgesic property
for atorvastatin (without morphine) at the speciﬁc doses in both
acute and chronic protocols in hot plate and tail ﬂick tests. Since,
the mechanisms underlying the protective role of statins on mor-
phine tolerance inhibition have not been extensively clariﬁed we
studied the possible involvement of nitrergic system in this process.
There is considerable evidence that endogenous NO is involved
in the modulation of morphine effects in various processes. It has
been shown that L-arginine-NO pathway mediates pain and prob-
ably plays a modulating role in the antinociceptive responses to
morphine (Brignola et al., 1994; Dambisya and Lee, 1995). Elevation
in NO has been implicated in the induction of morphine analgesic
tolerance and it was presumed that inhibition of NOS can attenuate
the development of tolerance (Bhargava 1995; Heinzen and Pollack,
2004). Evidence suggests that 7-NI and aminoguanidine may impair
the development of tolerance and also alters the downregulation
of morphine responsivity (Abdel-Zaher et al., 2006; Heinzen and
Pollack 2004).
Nitric oxide/cGMP pathway (especially at supraspinal site)
plays an important role in modulation of opioids analgesia and
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lso morphine-sensitive nociceptive processes. Babey et al. (1994)
howed that NG-nitro-l-arginine (NOArg) treatment prevents mor-
hine tolerance and L-arginine accelerates it and when L-arginine
as given alone decreased the potency of morphine. Thorat et al.
1993) suggested an important role for NO in development of
-opiate tolerance. Przewłocki et al. (1993) reported that NO is
nvolved in the spinal nociceptive events and elevated production
f NO following the nociceptive input could diminish the efﬁciency
f opioid antinociception in spinal cord. Dambisya and Lee (1996)
emonstrated that NO has a role in both phases of morphine toler-
nce and dependence: increase in NO levels during the induction
hase may  delay the development of opioid tolerance/dependence
hile inhibition of NOS could accelerate the development of tol-
rance and inhibition of NO attenuates the expression of both
olerance and physical dependence. Xu et al. (1998) demonstrated
hat inhibition of supraspinal NO system prevents the development
f acute morphine antinociceptive tolerance. However, enhanced
roduction of NO did not affect the magnitude of morphine toler-
nce.
Based on the previous reports, a complex linkage between ator-
astatin and NO production clearly exists (Amin-Hanjani et al.,
001; Laufs et al., 2000). Statin therapy modiﬁes the NOS expression
n pathological processes such as modulation of brain eNOS and
nhibiting the cytokine-mediated upregulation of iNOS in astro-
ytes and macrophages during cerebral ischemia which lead to
europrotection (Vaughan and Delanty, 1999). In case of in vitro
tudies, it has been demonstrated that statins prevent hypoxia
ediated downregulation of eNOS which is regulated by Rho, the
mall GTPase protein, through the inhibition of geranylgeranylpy-
ophosphate synthesis or Rho kinase (the downstream target)
Endres and Laufs, 2004; Wang et al., 2010; Zhou and Liao, 2009).
tudies indicated that atorvastatin treatment potently upregulates
ascular nNOS mRNAs and protein via Akt/NF-B signaling path-
ay, demonstrating a nNOS-mediated vascular effect for statins
Moezi et al., 2012; Nakata et al., 2007).
Our results showed that acute and chronic treatment of animals
ith L-NAME decreased the morphine analgesic efﬁcacy which was
levated due to atorvastatin treatment in hot plate test. To further
nderstand the effects of NOS isoforms, we examined the acute and
hronic co-administration of iNOS and nNOS inhibitors with effec-
ive dose of atorvastatin. These results indicated that both iNOS and
NOS could reverse the enhanced analgesic threshold of morphine
arose from atorvastatin) in the development phase. However, in
he expression phase we observed that only iNOS was  responsible
or atorvastatin potentiating effects in morphine analgesic latency.
cute co-administration of L-arginine with sub-effective dose of
torvastatin (acute) resulted in the enhancement of antinociceptive
hreshold of morphine.
The effects of NO may  be both protective and harmful during
orphine analgesic tolerance. NOS inhibitors themselves at effec-
ive doses could reverse the morphine tolerance, but in our study
n order to investigate the possible mechanism for protective effect
f atorvastatin in tolerance reversal, we selected the non-effective
oses for NOS inhibitors and inducers based on our previous studies
Javadi et al., 2013; Homayoun et al., 2002). Our results showed that
torvastatin protective effects are possibly mediated by increasing
he level of NO. This achievement is in line with Dambisya and Lee
1996) but in contrast with others.
An interesting ﬁnding in this study demonstrated that the
otent and selective inhibitor of NO-sensitive guanylyl cyclase
ODQ) could completely inhibit the protective effects of ator-
astatin therapy in both development and expression phases of
orphine tolerance. Nitric oxide pathway exerts several of its phys-
ological actions with soluble guanylyl cyclase stimulation (Moro
t al., 1996). Guanylyl cyclase is an intracellular receptor for gaseous
igand (NO) which induces the generation of cGMP, protein kinase Bulletin 125 (2016) 173–180 179
G (PKG) phosphorylation and changes in the activity of effector
proteins such as phosphodiesterases, ion pumps and ion channels
(Dupont et al., 2014).
In summary, our data reported that atorvastatin could be used
along with morphine to restore morphine analgesic properties dur-
ing development and expression phases of tolerance, suggesting a
novel approach in the treatment of morphine analgesic tolerance
which is clinically important. Moreover, we  also pointed out for
the ﬁrst time that NO/sGC/cGMP signaling pathway contributes to
alleviating effects of atorvastatin in morphine analgesic tolerance.
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